Explore the importance of GMP-grade plasmid DNA (pDNA) in cell and gene therapies, the challenges in global supply, and how ...

The Board of 4basebio plc is pleased to report the results for the financial year ended 31 December 2024. The annual report and accounts together with a notice of the Company’s annual general meeting, ...

4basebio reported strong progress for the year ended 31 December on Tuesday, with revenue doubling from DNA sales to £0.93m ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed ...

(NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an ...

Technology Networks interviewed Dr. Pooja Swali, the first author of a new study that conducted a pangenome analysis to trace ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.

Thermo Fisher Scientific has introduced the Applied Biosystems™ MagMAX™ Pro HT NoSpin Plasmid MiniPrep Kit to meet the ...

Most relapsing fever bacteria that infect humans are spread by ticks, but Borrelia recurrentis is unique in being transmitted between humans via body ...

Somatic hypermutation (SHM) of immunoglobulin variable (V) regions modulates antibody-antigen affinity is initiated by activation-induced cytidine deaminase (AID) on single-stranded DNA (ssDNA).

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...